

In the claims:

1-89. (Cancelled)

90. (New) A method of inhibiting human immunodeficiency virus (HIV) budding, the method comprising subjecting an HIV infected cell to at least an active portion of a polypeptide being at least 90 % homologous to SEQ ID NO: 2, said polypeptide being for inhibiting vesicle budding from said HIV infected cell.

91. (New) The method of claim 90, wherein said polypeptide is as set forth in SEQ ID NO: 2, 4 or 6.

92. (New) The method of claim 90, wherein said active portion of said polypeptide is as set forth in amino acid coordinates 490-723 of SEQ ID NO: 2.

93. (New) The method of claim 90, wherein said active portion of said polypeptide is as set forth in amino acid coordinates 647-723 of SEQ ID NO: 2.

94. (New) The method of claim 90, wherein said active portion of said polypeptide is as set forth in amino acid coordinates 647-665 of SEQ ID NO: 2.

95. (New) The method of claim 90, wherein said active portion of said polypeptide is as set forth in amino acid coordinates 647-667 of SEQ ID NO: 2.

96. (New) The method of claim 92, wherein said active portion of said polypeptide is encoded by nucleotide coordinates 1556-2255 of SEQ ID NO: 1.

97. (New) The method of claim 93, wherein said active portion of said polypeptide is encoded by nucleotide coordinates 2025-2255 of SEQ ID NO: 1.

98. (New) The method of claim 94, wherein said active portion of said polypeptide is encoded by nucleotide coordinates 2025-2079 of SEQ ID NO: 1.

99. (New) The method of claim 95, wherein said active portion of said polypeptide is encoded by nucleotide coordinates 2019-2088 of SEQ ID NO: 1.